ValiRx plc (LON:VAL)
0.17p-2.86%
Spriggl Score: Weak— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“Auditors flag going-concern risk; serial dilution threatens total loss despite recent capital raise extending runway.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About ValiRx plc
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a refo…
- Sector:
- Healthcare
- Industry:
- Biotechnology
- Market Cap:
- £2.3M
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across ValiRx plc and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free